Please assess the completion status of the following clinical trial:

Trial Title: Fetal and Infant Effects of Maternal Buprenorphine Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current opioid dependence as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-R criteria~* 18-40 years of age with uncomplicated singleton pregnancies~* Accurate gestational age dating verified by ultrasound~* Gestation of less than 34 weeks~* Stabilization on buprenorphine for one week prior to study procedures~Exclusion Criteria:~* Complications of pregnancy, including gestational diabetes, polyhydramnios, hypertension, placenta previa or significant risk of preterm delivery (i.e. incompetent cervix)~* Evidence of fetal malformation detected by prenatal ultrasound~* Significant general maternal health problems that can affect fetal functioning, including Type I or gestational diabetes, alterations in thyroid functioning, HIV infection or hypertension.~* Significant maternal psychopathology that would preclude informed consent (i.e. schizophrenia)~* Alcohol dependency per DSM IV R criteria (see ascertainment methods below)~* Women stable on methadone maintenance (defined as more than 3 days of methadone dosing)~* Women entering drug treatment reporting using street methadone (for more than 3 days)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Maternal buprenorphine treatment (Type: EXPERIMENTAL): Buprenorphine maintenance during pregnancy

Based on this trial design, predict the completion outcome and termination type (if applicable).